The challenges facing biotechs amid the ongoing financial fallout have resulted in the winding down of one US biotech, Vor Bio, and job losses at a clutch of other firms. Cambridge, ...
Mindjet, the world's leading enterprise SaaS platform for Innovation Management, today announced an updated release to ...
Conference Sponsorship Opportunities Are Available RALEIGH, N.C., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Percona ( the company that delivers enterprise-class MySQL, MariaDB ...
SAN FRANCISCO--(BUSINESS WIRE)--Vor Systems, an AI-enabled transaction platform built for complex renewable energy deals, today announced it has raised $3 million in pre-seed funding led by Gigascale ...
load I tested for this F&S Bullet Lab is, as the name indicates, loaded with latter. In many rifles, these bullets shoot just as well as match bullets. And finally, these bullets contain no lead. Not ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Vor Biopharma (VOR) rose ~17% on Tuesday after J.P. Morgan initiated its coverage with an Overweight recommendation and a Dec. 2026 price target of $43, citing a potential blockbuster status for the ...
Investing.com - JPMorgan has initiated coverage on Vor Biopharma, Inc. (NASDAQ:VOR) with an Overweight rating and a price target of $43.00, highlighting the potential of the company’s telitacicept ...
Vor Biopharma Inc. (VOR) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...
Vor Biopharma has rebounded from near-delisting by securing global rights (ex-China) to telitacicept, a promising autoimmune therapy. VOR's telitacicept targets multi-billion dollar autoimmune markets ...
While Vor provided no details on the results, the company is now evaluating a global trial of the drug in the chronic immune condition. Vor hit reset in May, after nearly a decade of work on blood ...
Vor Bio has handed Dallan Murray a swift return to the workforce. Weeks after being let go by Sarepta Therapeutics, Murray has landed the chief commercial officer post in Vor’s new-look C-suite.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results